Your session is about to expire
← Back to Search
Cariprazine treatment for Attention Deficit Hyperactivity Disorder (ADHD) (ADHD Trial)
ADHD Trial Summary
This trial will test the hypothesis that cariprazine will be an effective adjunctive treatment to long-acting psychostimulants in patients with ADHD.
- Attention Deficit Hyperactivity Disorder (ADHD)
ADHD Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2011 Phase 3 trial • 497 Patients • NCT01058668ADHD Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Am I eligible to partake in this research endeavor?
"This clinical trial is recruiting 15 participants aged 18 to 70 who are suffering from attention deficit hyperactivity disorder (ADHD). To qualify for the study, individuals must meet numerous criteria including providing written consent, having a primary diagnosis of ADHD as confirmed by DSM-5 and MINI 7.0.2 tests, scoring an Adult Self-Report Scale of ≥ 4 in Part A at Screening and Baseline visits, being on stable doses of psychostimulants or any other psychotropic medications apart from antipsychotics for more than 4 weeks prior to enrollment; passing all biochemical screens such as electrolytes levels assessment and urinalysis with"
How many participants is this medical experiment enrolling?
"Affirmative. According to clinicaltrials.gov, this medical trial is in a state of active recruitment following its initial posting on December 1st 2021 and subsequent editing on the 13th of that same month. The study demands 15 participants from one designated site."
Are there vacancies for participants in this medical experiment?
"This trial, first posted on December 1st 2021 and most recently updated on the 13th of that same month, is currently searching for participants as indicated by clinicaltrials.gov."
Is this the inaugural research effort of its kind?
"Cariprazine has been under investigation since 2019 when the first research trial, sponsored by Allergan and enrolling 330 patients, took place. Subsequent Phase 3 drug approval enabled 8 studies to be conducted across 58 cities in 12 countries."
Is the age limit for this experiment restricted to octogenarians or younger?
"To be eligible for this study, individuals must fall within the 18 to 70 year old age range. For those younger than 18 or older than 65, there are 110 and 41 clinical trials respectively that may better suit their needs."
To what extent might Cariprazine be a hazard for those undergoing treatment?
"Cariprazine therapy has been given a score of 3 due to the fact that this is already an approved treatment in its fourth phase of clinical trials."
Are there any additional examinations that have investigated the use of Cariprazine?
"Currently, 8 clinical trials examining the effects of Cariprazine are active. Of these studies, 5 have reached Phase 3. These investigations can be found in 189 locations with a concentration within Nis and New york City."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How responsive is this trial?
Typically responds via
Most responsive sites:
- START Clinic for Mood and Anxiety Disorders: < 48 hours
Average response time
- < 2 Days
Share this study with friends
Copy Link
Messenger